<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240721062500N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-08-25</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>the effects of low level laser therapy on osteointegration on posterior implants</public_title>
      <acronym></acronym>
      <scientific_title>Effect of Low-Level Laser Therapy on Osseointegration of Posterior Dental Implants: A Randomized, Double-Blind, Split-Mouth Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-07-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>17</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/78441</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study will use a simple randomization method with a split-mouth design. The randomization process will be as follows: - Randomization unit: Individual patient's mouth sides (right vs left) - Randomization tool: Computer-generated random number sequence - Sequence generation: A statistician not involved in the study will generate a random sequence using statistical software (e.g., R or SAS) - Allocation concealment: Opaque, sealed envelopes will be used. Each envelope will contain the allocation for the right side of the mouth (laser or control), with the left side automatically assigned to the opposite group. - Implementation: After the patient is deemed eligible and has signed the informed consent, the treating clinician will open the envelope to determine which side receives the laser treatment. The split-mouth design ensures that each patient serves as their own control, reducing inter-individual variability.(  1. A statistician outside the research team generates a random list of 0s and 1s, equal to the number of patients, using R software (version 4.1.2). The number 0 indicates laser allocation to the right side, and 1 indicates laser allocation to the left side. 2. This random list is placed in opaque, sealed envelopes. Each envelope is marked with a serial number corresponding to the patient's entry number into the study. 3. After confirming the patient's eligibility and signing the informed consent form, the research assistant (who is not involved in the treatment process) opens the envelope for that patient and informs the surgeon of the allocation. 4. Based on this allocation, the surgeon performs the laser treatment on the specified side. The opposite side is automatically assigned to the control group. 5. Each patient's allocation is recorded on a separate form accessible only to the research assistant and the surgeon. This method ensures that the allocation is completely random and cannot be predicted or manipulated.), Blinding description: This study is designed as a randomized, double-blind clinical trial: 1. Patients (Participants): Patients are blinded to which side of their mouth is receiving laser treatment and which side is the control group. They do not know in which sessions the laser is active and in which it is turned off. 2. Evaluators: The individuals responsible for measuring implant stability using the Ostell device are blinded to which side has received laser treatment and which is the control group. They simply perform the measurements without knowledge of the implant grouping. The principal investigator and the treatment team applying the laser cannot be blinded as they need to know which side to treat with the active laser and which with the inactive laser. Statistical analysts can also be kept blinded by providing them with coded data without specifying the groups. This type of blinding helps reduce bias in the evaluation of results, as neither patients nor evaluators are aware of the grouping. Additionally, the use of an inactive laser in the control group (instead of not using the device at all) helps maintain patient blinding, as they cannot discern whether they have received actual laser treatment or not. The main researcher and the treatment team applying the laser cannot be blinded, as they need to know which side to treat with the active laser and which with the inactive one. Statistical analysts can also be kept blinded by providing them with coded data without specifying the groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Osseointegration of posterior implants.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Low-level laser therapy (LLLT) with 940 nm wavelength, 100 mW output power, in continuous mode, for 40 seconds from buccal and lingual sides, on days 2, 4, 6, 8, 10, and 12 post-surgery. Intervention 2: Control group: Low power off laser (LLLT), in continuous mode, for 40 seconds from the buccal and lingual side, on days 2, 4, 6, 8, 10 and 12 after surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identification of individuals.

When:
The access period begins immediately after the publication of results.

To whom:
The data will be available to researchers working in academic and scientific institutions. Those working in industry can also apply to receive the data.

Conditions:
The data and documents from this study are to be used solely for research purposes and in compliance with confidentiality principles. Access to the data is permitted only for the research team, and any publication of results will be without mentioning patients' personal information.

Where to obtain:
To obtain data or documents related to this study, please contact the principal investigator, Dr. [Negar Asgarian], via email :Asgariann4001@mums.ac.ir . Requests will be addressed after review and approval by the university's research ethics committee.

How to obtain:
Submit a written request to the principal investigator
Review of the request by the research team
Evaluation and approval of the request by the research ethics committee
If approved, signing of a confidentiality agreement by the requester
Provision of data or documents in coded form without patients' personal information

This process typically takes 2 to 4 weeks.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Negar Asgarianomran</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Dentistry, Vakilabad Blvd, Mashhad , Iran</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177899191</zip>
        <telephone>+98 11 4329 4105</telephone>
        <email>asgarianN4001@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Negar Asgarianomran</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mashhad university of dentistry</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9177899191</zip>
        <telephone>+98 11 4329 4105</telephone>
        <email>asgarianN4001@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients should have sufficient bone volume for implant placement without GBR (Guided Bone Regeneration)
Patients should have signed an informed consent form
The target bone should be type D3 or D4.
Patient cooperation should be excellent</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>85 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with insufficient bone volume requiring GBR
Bone type D1 or D2
Need for implants in areas other than mandibular premolars and molars
Need for implants only on one side of the mandible (inability to perform split-mouth design)
Systemic diseases affecting bone healing process
Use of medications affecting bone metabolism
History of radiotherapy in the head and neck region</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Low-level laser therapy (LLLT) with 940 nm wavelength, 100 mW output power, in continuous mode, for 40 seconds from buccal and lingual sides, on days 2, 4, 6, 8, 10, and 12 post-surgery</i_keyword>
      <i_keyword>Control group: Low power off laser (LLLT), in continuous mode, for 40 seconds from the buccal and lingual side, on days 2, 4, 6, 8, 10 and 12 after surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Implant stability measured by Ostell device on days 0, 10, 21, and 42 post-surgery. Timepoint: On days 0, 10, 21, and 42 post-surgery. Method of measurement: Implant stability measured by Ostell device.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-06-08</approval_date>
        <contact_name>Ethics committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Khorasan Razavi, Mashhad, In front of Mellat Park - Faculty of Dentistry mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
